Suggested remit: To appraise the clinical and cost effectiveness of toripalimab with chemotherapy within its marketing authorisation for treating recurrent or metastatic nasopharyngeal cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6406
Provisional Schedule
- Committee meeting:
- 05 August 2026
- Expected publication:
- 02 December 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- Leo Pharma (Toripalimab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Barretts UK
- Black Health Agency for Equality
- Cancer Black Care
- Cancer Laryngectomee Trust
- Cancer52
- Changing Faces
- Get-A-Head
- Head and Neck Cancer UK
- Heartburn Cancer UK
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Let’s Face it
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Mouth Cancer Foundation
- National Association of Laryngectomee Clubs
- OG Support
- OPA Cancer Charity Oesophageal and Gastric Support
- Oracle Head and Neck Cancer
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Swallows Head & Neck Cancer Support Group
- Tenovus Cancer Care
- Professional groups
- Association of Cancer Physicians
- British Association of Head and Neck Oncologists
- British Association of Head and Neck Oncology Nurses
- British Association of Oral and Maxillofacial Surgeons
- British Association of Otorhinolaryngologists
- British Dietetic Association- Oncology Specialist Group
- British Geriatrics Society
- British Institute of Radiology
- British Oculoplastic Surgery Society
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Skull Base Society
- Cancer Research UK
- Oral Health Foundation
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Amarox Ltd (cisplatin, capecitabine)
- Bristol Myers Squibb (paclitaxel)
- Dr Reddys Laboratories (capecitabine)
- Genus (paclitaxel)
- Glenmark Pharmaceuticals (capecitabine)
- Hospira UK (cisplatin, gemcitabine, fluorouracil, docetaxel, paclitaxel)
- Medac Pharma (fluorouracil)
- Sandoz Ltd (cisplatin)
- Seacross Pharmaceuticals (docetaxel, paclitaxel)
- Sun Pharmaceuticals (gemcitabine)
- Synchrony Pharma (gemcitabine)
- Teva UK (paclitaxel)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
- Oracle Cancer Trust
- Saving Faces
- The Head and Neck Cancer Foundation
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 January 2026 | Invitation to participate |
| 13 November 2025 - 11 December 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6406 |
| 29 July 2025 | In progress. Following on advice received from the company, this appraisal has been scheduled back into the work programme. The appraisal is now anticipated to begin during early January 2026 when we will write to you about how you can get involved. |
| 11 April 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 21 February 2024 | Topic selection |
| 02 May 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual